» Articles » PMID: 26573548

The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis

Overview
Journal Semin Nephrol
Specialty Nephrology
Date 2015 Nov 18
PMID 26573548
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Nephritis is a common complication of systemic lupus erythematosus for which current therapies often prove inadequate. Current lupus nephritis classification systems emphasize glomerular acuity and scarring. However, tubulointerstitial inflammation (TII) and scarring are much better predictors of progression to renal failure. It now is becoming clear that the immunologic features, and probable underlying mechanisms, are very different in lupus glomerulonephritis and TII at the time of biopsy. Although glomerulonephritis is a manifestation of systemic autoimmunity, TII is associated with local in situ adaptive immune cell networks predicted to amplify local inflammation and tissue damage. In addition, poorly defined networks of innate immune cells and effectors likely contribute to the severity of local inflammation. Defining these in situ immune mechanisms should lead to a better understanding of prognostically meaningful lupus nephritis subsets and show novel therapeutic opportunities.

Citing Articles

Coexisting Tubulointerstitial Inflammation and Damage Is a Risk Factor for Chronic Kidney Disease in Patients With Lupus Nephritis.

Jeong H, Choi S, Kang J, Lee J, Choi Y, Park D Int J Rheum Dis. 2024; 27(12):e15444.

PMID: 39641495 PMC: 11622734. DOI: 10.1111/1756-185X.15444.


An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes.

Wendt R, Sobhani A, Diefenhardt P, Trappe M, Volker L Biomedicines. 2024; 12(10).

PMID: 39457572 PMC: 11504437. DOI: 10.3390/biomedicines12102259.


SAP-expressing T peripheral helper cells identify systemic lupus erythematosus patients with lupus nephritis.

Gartshteyn Y, Geraldino-Pardilla L, Khalili L, Bukhari S, Lerrer S, Winchester R Front Immunol. 2024; 15:1327437.

PMID: 38550577 PMC: 10972949. DOI: 10.3389/fimmu.2024.1327437.


Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy.

Shao D, Jimenez A, Guerrero M, Wang S, Broder A Res Sq. 2024; .

PMID: 38343803 PMC: 10854289. DOI: 10.21203/rs.3.rs-3867933/v1.


Kidney Biopsy in Management of Lupus Nephritis: A Case-Based Narrative Review.

Rodriguez-Ramirez S, Wiegley N, Mejia-Vilet J Kidney Med. 2024; 6(2):100772.

PMID: 38317756 PMC: 10840121. DOI: 10.1016/j.xkme.2023.100772.


References
1.
Boswell J, Yui M, Burt D, Kelley V . Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol. 1988; 141(9):3050-4. View

2.
Odegard J, DiPlacido L, Greenwald L, Kashgarian M, Kono D, Dong C . ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J Immunol. 2009; 182(7):4076-84. PMC: 2746004. DOI: 10.4049/jimmunol.0800758. View

3.
LeBleu V, Sugimoto H, Miller C, Gattone 2nd V, Kalluri R . Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest. 2008; 88(3):284-92. DOI: 10.1038/labinvest.3700715. View

4.
Lin S, Castano A, Nowlin B, Lupher Jr M, Duffield J . Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol. 2009; 183(10):6733-43. DOI: 10.4049/jimmunol.0901473. View

5.
Uppal S, Hayat S, Raghupathy R . Efficacy and safety of infliximab in active SLE: a pilot study. Lupus. 2009; 18(8):690-7. DOI: 10.1177/0961203309102557. View